retatrutide clinical trial results 2024 2025 press release New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide Dosing Guide: 1-12 mg

Sermorelin alone patients new to peptide therapy, those focused on sleep and general anti-aging, patients who prefer the simplest daily protocol, and those who value the historically FDA-approved molecule status

However, the combined gastrointestinal burden may be more challenging to tolerate, and the risk of dehydration leading to acute kidney injury is increased

Foundayo: New Oral GLP-1 Option (April 2026) Oral Alternative Now Available Foundayo (orforglipron) is Eli Lilly's new oral GLP-1 medication, FDA-approved in April 2026

[DOI] [PubMed] [Google Scholar] 35.Nathan DM, Buse JB, Davidson MB, et al

GOLO VS